CTRI/2012/04/002591已完成3 期
A multicentric open clinical trial to ascertain the role of homoeopathic therapy in vitiligo
Central Council for Research in Homoeopathy New Delhi0 个研究点目标入组 500 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •All the cases presenting with Vitiligo without any systemic disorder, residing with in approachable distance from the centre.
排除标准
- •Cases suffering from associated diseases:
- •Severe systemic disease (such as Diabetes mellitus/ Hypertension, etc.)
- •Pernicious Anaemia
- •Alopecia Areata
- •Lichen planus
- •Downâ??s Syndrome
- •Hypo/hyperthyroidism
- •Addisons Disease
- •Graves Disease
研究者
相似试验
进行中（未招募）
不适用
An open multicenter clinical trial to evaluate the safety, tolerability and efficacy of Deferasirox (ICL670) in patients affected by Myelodysplastic syndrome and transfusional chronic hemosiderosis. - GIMEMA MDS 0306ow and intermediate I risk (IPSS score) Myelodysplastic syndrome and transfusion-induced hemosiderosis.MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2006-006147-31-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
进行中（未招募）
不适用
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.partial seizures with or without secondary generalizationMedDRA version: 6.0Level: LLTClassification code 10034089EUCTR2004-002322-22-DESCHWARZ BIOSCIENCES Inc.160
进行中（未招募）
1 期
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalizatioEUCTR2004-002322-22-CZSCHWARZ BIOSCIENCES, Inc.160
进行中（未招募）
不适用
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.EUCTR2004-002322-22-SESCHWARZ BIOSCIENCES Inc.160
进行中（未招募）
不适用
A multi-center, open-label trial to investigate the safety and tolerability of intravenous SPM 927 as replacement for oral SPM 927 in subjects with partial seizures with or without secondary generalization.EUCTR2004-002322-22-LTSCHWARZ BIOSCIENCES Inc.100